Q2 2025 13F Holders as of 6/30/2025
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
4.56M
-
Number of holders
-
330
-
Total 13F shares, excl. options
-
310M
-
Shares change
-
+5.46M
-
Total reported value, excl. options
-
$1.57B
-
Value change
-
+$26.5M
-
Put/Call ratio
-
0.8
-
Number of buys
-
164
-
Number of sells
-
-147
-
Price
-
$5.06
Significant Holders of RECURSION PHARMACEUTICALS, INC. - Common Stock (RXRX) as of Q2 2025
418 filings reported holding RXRX - RECURSION PHARMACEUTICALS, INC. - Common Stock as of Q2 2025.
RECURSION PHARMACEUTICALS, INC. - Common Stock (RXRX) has 330 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 310M shares
.
Largest 10 shareholders include VANGUARD GROUP INC (36.1M shares), ARK Investment Management LLC (33M shares), BlackRock, Inc. (28.4M shares), BAILLIE GIFFORD & CO (24.2M shares), SOFTBANK GROUP CORP. (14.7M shares), KINNEVIK AB (PUBL) (13.4M shares), Mubadala Investment Co PJSC (13M shares), STATE STREET CORP (11.2M shares), NOVO HOLDINGS A/S (9.67M shares), and MIC Capital Management UK LLP (9.64M shares).
This table shows the top 330 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.